Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 963.35%.

  • Pharma's EBITDA Margin fell 5429600.0% to 963.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 585.9%, marking a year-over-year increase of 4764000.0%. This contributed to the annual value of 562.63% for FY2025, which is 4064400.0% up from last year.
  • Latest data reveals that Pharma reported EBITDA Margin of 963.35% as of Q3 2025, which was down 5429600.0% from 488.41% recorded in Q2 2025.
  • Over the past 5 years, Pharma's EBITDA Margin peaked at 360.91% during Q1 2025, and registered a low of 7721.43% during Q3 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 977.29% (2024), whereas its average is 1871.7%.
  • Examining YoY changes over the last 5 years, Pharma's EBITDA Margin showed a top increase of 80862100bps in 2021 and a maximum decrease of -65094300bps in 2021.
  • Pharma's EBITDA Margin (Quarter) stood at 1622.54% in 2021, then skyrocketed by 57bps to 695.78% in 2022, then tumbled by -292bps to 2730.88% in 2023, then skyrocketed by 74bps to 718.68% in 2024, then tumbled by -34bps to 963.35% in 2025.
  • Its EBITDA Margin was 963.35% in Q3 2025, compared to 488.41% in Q2 2025 and 360.91% in Q1 2025.